QUOTE AND NEWS
SeekingAlpha  Aug 15  Comment 
By John Vincent: This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's U.S. stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/14/2014. Please visit our...
SeekingAlpha  Aug 6  Comment 
ByPrescient Investment Analysis: Gilead Sciences (NASDAQ:GILD) is one of the more compelling companies on the market. Anyone who is familiar with the company is aware that Sovaldi is hailed as a cure for hepatitis C, and prevents the need for...
newratings.com  Aug 5  Comment 
WHITEHOUSE STATION (dpa-AFX) - Healthcare giant Merck & Co. Inc. (MRK) Tuesday announced the successful completion of the tender offer for all shares of Idenix Pharmaceuticals, Inc. (IDIX) at a purchase price of $24.50 per share. As of the tender...
SeekingAlpha  Aug 4  Comment 
Here's the list of our Outstanding Performance Award Winners to date. We will be updating weekly: Winners on July 28, 2014 Unconventional Capital Wisdom - Long IDIX (Idenix Pharmaceuticals), July 30, Complete Story »
SeekingAlpha  Jul 28  Comment 
Congratulations to our first two Outstanding Performance award winners: Winner #1: IDIX (Idenix Pharmaceuticals) by Unconventional Capital Wisdom, July 30, 2013. +597% Winner #2: FNHC (Federated National Holdings Company) by Nitor Capital,...
SeekingAlpha  Jul 18  Comment 
Track how today's Stocks To Watch are performing here. To send in your own ideas for next week's Stocks To Watch, email stockstowatch@seekingalpha.com before 6:00 AM ET Monday. Idenix Pharmaceuticals ( IDIX ) - long - ...
Benzinga  Jul 3  Comment 
The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: IDIX). Benzinga spoke to Enanta (NASDAQ: ENTA) CEO Jay Luly about possibilities for his firm, which has one...
Benzinga  Jun 27  Comment 
Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive acquisition, earlier this month, sent shares of other Hep C companies, Enanta (NASDAQ: ENTA) and Achillion (NASDAQ:...
Benzinga  Jun 20  Comment 
Baird analyst Brian Skorney reported on “increasingly bullish” share action of Achillion Pharmaceuticals (NASDAQ: ACHN) following SEC filing by Idenix Pharmaceuticals (NASDAQ: IDIX). Skorney remarked that Achillion's stock action has been...
SeekingAlpha  Jun 20  Comment 
ByAustrolib: Merck's (MRK) acquisition of Idenix (IDIX) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have been published on Seeking Alpha alone on the merger since the $3.85B...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki